BIAS
AST

Beacon Investment Advisory Services’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Beacon Investment Advisory Services’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,000
Closed -$21K – 271
2018
Q3 		$21K Hold
16,000
– – ﹤0.01% 254
2018
Q2 		$22K Buy
16,000
+5,500
+52% +$8.43K ﹤0.01% 252
2018
Q1 		$15K Buy
+10,500
New +$21.9K ﹤0.01% 256

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Beacon Investment Advisory Services's AST Position: Q4 2018 in Review

Beacon Investment Advisory Services sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 16,000 shares — an estimated $21K sold.

Beacon Investment Advisory Services first reported a position in AST in Q1 2018 and held it in 3 quarters. The position peaked at $22K in Q2 2018. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

  • Beacon Investment Advisory Services reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
  • Beacon Investment Advisory Services sold 16,000 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $21K.
  • Beacon Investment Advisory Services first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2018 and held it in 3 quarters.
  • Beacon Investment Advisory Services's Asterias Biotherapeutics Inc. Series A position peaked at $22K in Q2 2018.
  • 46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Beacon Investment Advisory Services's 13F filing for Q4 2018, filed 8 Feb 2019.